Radiopharmaceuticals company Navidea Biopharmaceuticals (NYSE Amex:NAVB) has opened a Boston-area commercialization office.
Employees at Navidea’s new Andover, Massachusetts office will focus much of their attention on the expected launch later this year of drug candidate Lymphoseek, a targeting agent used by surgeons to identify lymph nodes in patients with breast cancer or melanoma and to indicate whether cancer has spread to a particular lymph node.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Lymphoseek is in the midst of a review by the U.S. Food and Drug Administration and could be approved for sales and marketing as soon as this summer.
Navidea’s corporate headquarters, with clinical, manufacturing, regulatory and administration functions, will remain in Dublin, Ohio, according to a statement from the company.
Navidea, which until earlier this year was known as Neoprobe, is also working toward European commercialization of Lymphoseek and last week reported obtaining “positive guidance” from regulators about a path forward for the drug.
The company plans by the end of the year to submit regulatory documents aimed at securing European marketing approval of Lymphoseek.
A Personalized Approach to Medication Nonadherence
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
[Photo from flickr user Manu_H]
